US equities |
NVDA $239.53 ▲+2.39% SPCX $170.12 ▲+7.02% MU $1,062.55 ▼-1.15% TSLA $379.42 ▲+2.38% SNDK $1,701.37 ▼-1.08% MSFT $526.51 ▲+1.74% INTC $116.31 ▼-2.53% META $742.70 ▲+2.01%
FinancialContent

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

4.280 +0.210 (+5.16%)
Delayed Quote Updated: 3:53 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 13, 2024 ↗
 
Via Benzinga
News headline image
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Where ARS Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Ratings For ARS Pharmaceuticals ↗
 
Via Benzinga
News headline image
ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
News headline image
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
News headline image
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray ↗
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it. 
Via Investor's Business Daily
News headline image
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 ↗
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment. 
Via Benzinga
News headline image
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned ↗
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >